Roll Back Malaria Partnership

Partnership Objectives

  1. Scale-up malaria control (prevention and treatment) in malaria endemic countries.
  2. Conduct resource mobilization to increase donor funding for malaria.
  3. Drive advocacy and increase public awareness about malaria.

24th RBM Board Meeting. The RBM Partnership has demonstrated how a strong, well-organized multi-stakeholder partnership can help deliver broad health benefits while relieving overburdened health systems. 24th RBM Board Meeting. The RBM Partnership has demonstrated how a strong, well-organized multi-stakeholder partnership can help deliver broad health benefits while relieving overburdened health systems. Copyright Roll Back Malaria

What are the health needs and challenges?

Malaria is a preventable and treatable disease transmitted by mosquitoes. It kills more than 600,000 people each year, most of them in sub-Saharan Africa, where malaria is the leading cause of death in children under five.

Because malaria is a global emergency that affects mostly poor women and children, the disease perpetuates a vicious cycle of poverty in the developing world. Malaria-related illnesses and mortality cost Africa’s economy alone USD 12 billion per year.

Today, malaria can be prevented, diagnosed and treated with a combination of available tools, but it takes global commitment. Estimates indicate that USD 4.2 billion is needed each year to fund the fight against malaria effectively.

Description of partnership activities and how they address needs and challenges

Roll Back Malaria (RBM) Partnership was launched in 1998 by the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), the United Nations Development Program (UNDP) and the World Bank. Its goal was to provide a coordinated global approach to fighting malaria.

The RBM Partnership is the global framework for implementing coordinated action against malaria. It mobilizes resources for action and forges consensus among partners. The Partnership is made up of more than 500 partners, including countries where malaria is endemic, their bilateral and multilateral development partners, the private sector, nongovernmental and community-based organizations, foundations, and research and academic institutions. The Global Malaria Action Plan defines two stages of malaria control: first, scaling-up for impact (SUFI) of preventive and therapeutic interventions, and then sustaining control over time.

RBM’s strength lies in its ability to form effective partnerships both globally and nationally. Partners work together to scale up malaria control efforts at country level, coordinating their activities to avoid duplication and fragmentation, and to ensure optimal use of resources. RBM’s strategy is to reduce malaria morbidity and mortality by implementing activities in all countries where malaria is endemic and by strengthening health systems. 

GlaxoSmithKline remains an active member of the private sector delegation and is currently a Board Member representing the private sector. GSK is also active in various working groups including the Malaria Advocacy Working Group, the Procurement & Supply Chain Management Working Group and the GMAP ll Task Force. GSK was involved in the launch of the Progress and Impact Report on A Decade of Partnership and Results.

Novartis is an active member of the private sector delegation to the RBM board and held the board seat from May 2010-2012. Today, Novartis continues its strong involvement in three RBM partner committees: Country/Regional Support Partner Committee, Strategic Communications Partner Committee, and Advocacy and Resource Mobilization Partner Committee. In 2009, with RBM and other partners, Novartis launched SMS for Life to help prevent stock-outs of antimalarials in Tanzania.  SMS for Life has since been rolled out in more than 10,000 public health facilities in Kenya, Ghana, the Democratic Republic of Congo and Cameroon. Over the years, the scope of the program has also expanded to more disease areas and health parameters. 

The malaria program is a flagship initiative of the Sanofi Access to Medicines department. It reflects the organization’s long term commitment to use its core skills to build a sustainable and comprehensive model to fight malaria on all fronts, from prevention to treatment. Sanofi and the Drugs for Neglected initiative (DNDi) have developed an artemisinin combination therapy: ASAQ (Artesunate Amodiaquine) Winthrop®. Sanofi also helps its partners in the field through a comprehensive set of Information Education and Communication tools and initiatives on the prevention, diagnosis and treatment of malaria, which are tailored to the needs of all stakeholders in the healthcare chain.

Lessons learned

The RBM Partnership has demonstrated how a strong, well-organized multi-stakeholder partnership can help deliver broad health benefits while relieving overburdened health systems.

Summary of impact and forward looking information

RBM has produced a series of Progress and Impact Reports that comprehensively document progress in the fight against malaria.

According to the report entitled ‘A Decade of Partnership and Results’, global malaria deaths have dropped by an estimated 38%, with 43 countries (11 of them in Africa) cutting malaria cases or deaths by 50% or more, reversing the trend of the previous decade and saving over a million lives.


Roll Back Malaria in Action

Malaria and Poverty

Partnership information

Company(ies) GlaxoSmithKline , Novartis , Sanofi

Partner(s) Abt Associates, African Leader Malaria Alliance (ALMA), Bestnet, Bill and Melinda Gates Foundation, Cameroon Coalition Against Malaria, Development Finance International, ExxonMobil, FHI Development 360, Friends of the Global Fund Africa, Global Fund to Fight AIDS, Tuberculosis and Malaria, Hill and Knowlton, Intelligent Insect Control, Management Sciences for Health (MSH), Multilateral Initiative on Malaria, Premier Medical Corporation, Roll Back Malaria Partnership (RBM), Shell International BV, Syngenta, Trop Med Pharma Consulting, UK Department for International Development (DFID), UNDP, UNICEF, United Nations Foundation, United Nations Special Envoy Office on Malaria, University of Melbourne, US President’s Malaria Initiative, Vestergaard-Frandsen, World Health Organization (WHO)

Type of Partner(s) Academia / Hospitals, Government, IGOs, Multilaterals, NGOs, Other Business

Therapeutic Focus Infectious Diseases

Disease(s) Malaria

Program Type(s) Availability of Treatment - Differential Pricing, Health System Infrastructure - Development of Physical Infrastructure, Health System Infrastructure - mHealth, Prevention Programs - Awareness & Outreach

Targeted Population(s) Children, Elderly, Marginalised / Indigenous People, Men, Mothers, People with low income, Women, Youth

Region(s) Europe & Central Asia, Latin America & Caribbean, Middle East & North Africa, South Asia, Sub-Saharan Africa

Number of Countries 77

Country(ies) Afghanistan, Algeria, Angola, Argentina, Azerbaijan, Bangladesh, Belize, Benin, Bhutan, Bolivia, Botswana, Brazil, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Colombia, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, India, Jamaica, Kenya, Lesotho, Liberia, Madagascar, Malawi, Maldives, Mali, Mauritania, Mauritius, Mexico, Mozambique, Namibia, Nepal, Niger, Nigeria, Pakistan, Paraguay, Peru, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sri Lanka, Sudan, Suriname, Swaziland, Tanzania, The Gambia, Togo, Turkey, Uganda, Zambia, Zimbabwe

Start Date 1998

More information Roll Back Malaria website

Anticipated completion date Ongoing